Retinoblastoma Clinical Trials

14 recruiting

Retinoblastoma Trials at a Glance

16 actively recruiting trials for retinoblastoma are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in New York, Milwaukee, and Los Angeles. Lead sponsors running retinoblastoma studies include Eye & ENT Hospital of Fudan University, Sun Yat-sen University, and Children's Oncology Group.

Browse retinoblastoma trials by phase

Treatments under study

About Retinoblastoma Clinical Trials

Looking for clinical trials for Retinoblastoma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinoblastoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinoblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

SarcomaEndocrine TumorsNeuroblastoma+2 more
National Cancer Institute (NCI)6,035 enrolled5 locationsNCT01109394
Recruiting

Retinoblastoma Patient Clinical Database and Tissue Repository

RetinoblastomaRetinoblastoma BilateralRetinoblastoma Unilateral
Children's Hospital Los Angeles800 enrolled9 locationsNCT04959097
Recruiting
Phase 2

Retinoblastoma Phase II Expanded Access Clinical Trial

Retinoblastoma
Targeted Therapy Technologies, LLC30 enrolled2 locationsNCT06679634
Recruiting

Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.

RetinoblastomaRetinoblastoma BilateralRetinoblastoma Unilateral+2 more
University of Washington100 enrolled1 locationNCT06725173
Recruiting

Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma

Retinoblastoma
French Africa Pediatric Oncology Group3,000 enrolled7 locationsNCT04425434
Recruiting
Phase 2

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Unilateral RetinoblastomaBilateral RetinoblastomaChildhood Intraocular Retinoblastoma+2 more
Children's Oncology Group26 enrolled20 locationsNCT05504291
Recruiting

Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?

Retinoblastoma
Fondation Ophtalmologique Adolphe de Rothschild60 enrolled1 locationNCT03267459
Recruiting
Phase 2Phase 3

Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

Retinoblastoma
Institut Curie225 enrolled28 locationsNCT04681417
Recruiting

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

Cancer SurvivorRetinoblastomaBiological Sibling+2 more
Vanderbilt-Ingram Cancer Center900 enrolled11 locationsNCT03932786
Recruiting

Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients

RetinoblastomaPediatric Retinoblastoma
Memorial Sloan Kettering Cancer Center75 enrolled1 locationNCT03546387
Recruiting
Early Phase 1

Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma

RefractoryRetinoblastoma
Eye & ENT Hospital of Fudan University2 enrolled1 locationNCT06424301
Recruiting
Early Phase 1

High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed

RetinoblastomaRetinoblastoma, Recurrent
Eye & ENT Hospital of Fudan University10 enrolled1 locationNCT06972602
Recruiting
Not Applicable

Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma

Retinoblastoma, Extraocular
Eye & ENT Hospital of Fudan University18 enrolled1 locationNCT04903678
Recruiting

Trilateral Retinoblastoma: Incidence and Outcomes

RetinoblastomaTrilateral Retinoblastoma
Amsterdam UMC, location VUmc4,351 enrolled1 locationNCT06367530
Recruiting
Phase 3

Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma

Retinoblastoma
Sun Yat-sen University500 enrolled1 locationNCT05080010
Recruiting
Phase 3

Topotecan and Melphalan for Retinoblastoma

Chemotherapy EffectRetinoblastoma
Sun Yat-sen University50 enrolled1 locationNCT04799002